S

Soleno Therapeutics

D
SLNO
USD
-0.835
(-1.561%)
Market Closed
20,215.00
Volume
-2.375
EPS
-
Div Yield
-28.773224
P/E
2,046,783,782.07
Market Cap
Today
-1.5610%
1 Week
6.116%
1 Month
3.043%
6 Months
20.824%
12 Months
1,067.517%
Year To Date
30.755%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SRNE
(%)
USD
V
VBIV
(%)
USD
A
AUPH
0.125
(1.768%)
USD
V
VSTM
0.105
(3.8674%)
USD
L
LXRX
0.04
(2.4242%)
USD
T
TRVN
-0.175
(-3.4688%)
USD
T
TNXP
0.0048
(3.3081%)
USD
A
ADVM
0.5
(7.1633%)
USD

Title:
Soleno Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet forthe treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Do you need help or have a question?
Contact Us